Coherus Announces Appointment of Dr. V. Bryan Lawlis, Jr. as Chairman of its Scientific Advisory Board

Coherus Announces Appointment of Dr. V. Bryan Lawlis, Jr. as Chairman of its 
Scientific Advisory Board 
REDWOOD CITY, Calif., Jan. 7, 2013 /CNW/ - Coherus BioSciences, Inc. 
("Coherus"), a biopharmaceuticals company dedicated to global development and 
commercialization of biologic therapeutics, announced today that it has 
appointed V. Bryan Lawlis, Jr., Ph.D., as Chairman to its Scientific Advisory 
Board. Dr. Lawlis, a 31-year biotech industry veteran, has extensive 
experience in manufacturing biotechnology and other pharmaceutical products, 
research and development of drug products, conducting clinical trials and the 
regulatory processes. 
"It is a privilege to have Dr. Lawlis, whose expertise in biologics will 
provide invaluable direction for our biosimilar programs," said Denny Lanfear, 
Chief Executive Officer of Coherus. "Navigating the complex and challenging 
biosimilar development pathway requires extraordinary domain expertise and 
nuanced insight to be successful. Bryan's expertise very effectively 
complements the world class biologic drug development team we have in place at 
"With my new appointment to the SAB, I will get the opportunity to help 
Coherus achieve success in addressing critical issues surrounding the use of 
biosimilars," said Dr. Lawlis. "I have been very impressed by Coherus' 
achievements with each of the products in their portfolio thus far. The 
company has identified a strong business model utilizing a high caliber team 
and support from several strategic partners to ensure significant value 
inflection points in the near future." 
About Dr. V. Bryan Lawlis, Jr. 
Dr. Lawlis is a founder and currently serves as the President and Chief 
Executive Officer of Itero Biopharmaceuticals, Inc., a privately held 
developer of value-added follow-on and novel therapeutic proteins and 
antibodies that was founded in 2006. Dr. Lawlis served as President and Chief 
Executive Officer of Aradigm Corporation from August 2004, and served on its 
Board of Directors from February 2005, continuing in both capacities until 
August 2006. Dr. Lawlis served as Aradigm Corporation's President and Chief 
Operating Officer from June 2003 to August 2004, and its Chief Operating 
Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded 
Covance Biotechnology Services, a contract biopharmaceutical manufacturing 
operation, served as its President and Chief Executive Officer from 1996 to 
1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth 
RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was 
employed at Genencor, Inc. and Genentech, Inc. His last position at Genentech 
was Vice President of Process Sciences. Dr. Lawlis currently holds board 
positions at Itero Biopharmaceuticals, Inc, Sutro Biopharma, Inc and BioMarin 
Pharmaceutical Inc. 
Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin 
and a Ph.D. in Biochemistry from Washington State University. 
About Coherus BioSciences 
Coherus BioSciences is an emerging biopharmaceutical company headquartered in 
the San Francisco Bay Area with an entirely new model for developing safe, 
high-quality biosimilar therapeutics. Founded in 2010, Coherus already has 
formed global partnerships with top tier pharma and filled the pipeline with 
five product candidates focused on treating oncology and inflammatory 
diseases. Led by a group of early biotech pioneers, Coherus has reinvented the 
entire business of developing biologic medicines, from concept to 
commercialization, so that more patients around the world can have greater 
access to quality therapeutics. For additional information, please visit 
PRN Photo Desk, 
SOURCE: Coherus BioSciences 
To view this news release in HTML formatting, please use the following URL: 
CO: Coherus BioSciences
ST: California
-0- Jan/07/2013 13:10 GMT
Press spacebar to pause and continue. Press esc to stop.